Abstract: The present invention relates to a pharmaceutical composition comprising an amorphous adsorbate of lenalidomide, or a pharmaceutically acceptable salt thereof, on a porous carrier and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of multiple myeloma and myelodysplastic syndromes.
Type:
Application
Filed:
December 16, 2015
Publication date:
December 28, 2017
Inventors:
Deepak MURPANI, Marta VIVANCOS MARTINEZ, Lisardo ALVAREZ FERNANDEZ, Luis NOGUEIRAS NIETO
Abstract: A composite capsule and a method of preparing the same are provided. The composite capsule includes: a raloxifene separate layer including raloxifene or a pharmaceutically acceptable salt thereof; and a vitamin D separate layer including vitamin D or a derivative thereof, wherein the raloxifene separate layer and the vitamin D separate layer are separated from one another in the composite capsule.
Type:
Application
Filed:
January 28, 2016
Publication date:
December 28, 2017
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Young Hun KIM, Taek Kwan KWON, Jin Young PARK, Seung Bin YOUN, Jae Hyun PARK, Jong Soo WOO, Yong Il KIM
Abstract: Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.
Abstract: This invention provides, among other things, tetrahydroisoquinolines useful for treating viral infections, pharmaceutical formulations containing such compounds, as well as methods of inhibiting the replication of a virus, such as HIV, or treating a disease, such as AIDS.
Type:
Application
Filed:
December 15, 2015
Publication date:
December 28, 2017
Inventors:
Andy ATUEGBU, Dennis SOLAS, Clarence R. HURT, Anatoliy KITAYGORODSKYY
Abstract: The present invention provides solid crystalline forms of apomorphine free base or a hydrate, solvate, or co-crystals thereof. Such crystalline forms may be advantageous over amorphous forms of apomorphine, e.g., amorphous salt forms such as acid addition salts of apomorphine, because of their increased/greater stability and/or improved pharmacological properties, e.g., decreased adverse reactions at the site of administration. The invention further provides liquid formulations obtained by dissolving said crystalline forms of apomorphine in a solvent, as well as a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, or a condition associated therewith, by administration of said liquid formulations.
Type:
Application
Filed:
December 23, 2015
Publication date:
December 28, 2017
Inventors:
Oron Yacoby-Zeevi, Mara Nemas, Jonathan Cummins, Petra Dieterich
Abstract: This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis.
Abstract: The subject invention provides a method of treating a subject afflicted with glaucoma, suffering from retinal ganglion cell (RGC) loss or damage, or elevated intraocular pressure (IOP), or of reducing RGC loss or damage, or reducing IOP in a subject, comprising administering to the subject an amount of laquinimod effective to treat the subject, to reduce RGC loss or damage, or to reduce IOP in the subject. Provide also is a pharmaceutical composition, a package and a therapeutic package for treating a subject afflicted with glaucoma.
Abstract: The present invention relates to methods for treating, preventing, or reducing the risk of microbial infections while minimizing adverse gastrointestinal effects using a two-stage dosing regimen comprising about 1 to about 7 days of intravenous administration followed by about 1 to about 14 days of oral administration of an antimicrobial agent.
Type:
Application
Filed:
September 6, 2017
Publication date:
December 28, 2017
Inventors:
Danping LI, Scott J. HOPKINS, Jarrod LONGCOR
Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
Type:
Application
Filed:
July 18, 2017
Publication date:
December 28, 2017
Inventors:
Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
Abstract: The present disclosure relates to cured pharmaceutical compositions designed to reduce the potential for improper administration of drugs that are subject to abuse, the process of curing such composition in order to improve the dissolution stability, method of using the same for treatment of pain.
Type:
Application
Filed:
July 13, 2017
Publication date:
December 28, 2017
Inventors:
Said SAIM, Alison B. Fleming, Ravi K. Varanasi
Abstract: The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.
Abstract: The embodiments described herein include methods and formulations for treating anaphylaxis and related acute allergic reactions. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
Abstract: Ophthalmic formulations containing tyrosine kinase inhibitors, such as Nintedanib, Axitinib, Sorafenib, and Pazopanib are described. The ophthalmic formulations can contain microparticles or nanoparticles of the tyrosine kinase inhibitor. Also described are methods of using the ophthalmic formulations for treating ocular surface diseases, such pterygium, including recurrent pterygium, and hyperemia associated with pterygium.
Abstract: A solid formulation includes pimobendan or a pharmaceutically acceptable salt thereof, which is homogenously dispersed with a polyvalent acid and a flavor suitable to animals.
Type:
Application
Filed:
September 5, 2017
Publication date:
December 28, 2017
Inventors:
Martin A. Folger, Bernhard Hassel, Stefan Henke, Jens Lehmann
Abstract: The invention relates to the provision of a new crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium, the use of this form for medical purposes, methods for producing the crystalline form according to the invention, as well as pharmaceutical preparations comprising said form.
Type:
Application
Filed:
December 18, 2015
Publication date:
December 28, 2017
Applicant:
METRIOPHARM AG
Inventors:
Thomas Martin, Josef Breu, Wolfgang Brysch, David Kosel, Beate Ludescher, Michael Niedermaier, Jörg Von Wegerer
Abstract: Provided is an ink composition less likely to cause offset and sticking. Provided is a printed matter and a printing method using such ink composition. The ink composition includes a (meth) acrylic resin and a drying oil, the (meth)acrylic resin: containing at least 40% by weight or more of a structural unit derived from (meth)acryl monomer having a straight-chain alkyl group having 4 or more carbon atoms, branched alkyl group having 4 or more carbon atoms, or cyclic alkyl group having 4 or more carbon atoms (1); having a glass transition temperature of 63° C. to 180° C. (2); and having a weight-average molecular weight of 1000 to 80,000 (3).
Abstract: The invention provides novel chemical compounds useful for treating cancer or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
Type:
Application
Filed:
June 30, 2017
Publication date:
December 28, 2017
Inventors:
Jonathan M. Miller, John B. Morris, Nancy E. Sever, Eric A. Schmitt, Ping X. Gao, Yi Shi, Yi Gao, Bernd Liepold, Anna Moosmann, Mirko Pauli, Fatih Durak, Thomas Kessler, Peter Hoelig, Karin Rosenblatt, Drazen Kostelac, Rajeev Gokhale, Mark Costello, Carl Knable
Abstract: The use of methotrexate, e.g., repeated dosing or sustained-release formulations of methotrexate, for treating or reducing risk of proliferative vitreoretinopathy (PVR) or epiretinal membranes (ERM), e.g., after surgical vitrectomy to treat retinal detachment.
Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.
Type:
Application
Filed:
September 8, 2017
Publication date:
December 28, 2017
Inventors:
Eva Ulrike GRAEFE-MODY, Thomas KLEIN, Michael MARK, Hans-Juergen WOERLE
Abstract: The present invention relates to the use of 4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound A), more particularly (+)-4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound A?), for treating leukemias, in particular acute leukemias, preferably acute myeloid leukemias.
Abstract: The present invention relates to methods of treating tuberculosis, including multidrug resistant varieties and latent tuberculosis. More particularly, the present invention relates to a method of treating tuberculosis in a mammal comprising administering to said mammal in need thereof an effective amount of a compound of formula (T), (S)—N-[[3-[3-fluoro-4-(4-thiomor-pholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, or a pharmaceutically acceptable salt thereof in combination with at least two agents useful in the treatment of tuberculosis. The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, (ii) a therapeutically effective amount of at least one agent useful in the treatment of tuberculosis and (iii) one or more pharmaceutically acceptable carriers or vehicles.
Type:
Application
Filed:
July 10, 2017
Publication date:
December 28, 2017
Applicants:
PFIZER INC., THE JOHNS HOPKINS UNIVERSITY
Inventors:
Steven J. BRICKNER, Eric NUERMBERGER, Charles K. STOVER
Abstract: The present invention provides a tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide.
Type:
Application
Filed:
January 22, 2016
Publication date:
December 28, 2017
Inventors:
David Andrew Coates, Craig Daniel Wolfangel
Abstract: This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL.
Abstract: This invention provides methods and compositions for treating nicotine addiction or treating or preventing nicotine cravings in a subject. The method comprises administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof.
Abstract: A technique is provided for reducing the discoloration of an aqueous composition containing a halogenated isoquinoline derivative during high-temperature preservation. An aqueous composition comprising a compound represented by Formula (1): wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a prostaglandin.
Abstract: The invention relates to compositions and formulations comprising isolated acidic fraction of mastic gum and uses thereof for treating impaired neurological functions as well as wound and tissue repair.
Abstract: Provided is a method of treating metabolic diseases including type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia, obesity, hepatic steatosis, and hyperinsulinemia in a subject in need, including the step of administering to the subject a therapeutically effective amount of antcin K. Also provided is a method of enhancing protein expression ratio of phospho-5? adenosine monophosphate-activated protein kinase (phospho-AMPK) to total AMPK in skeletal muscle or liver of a subject, and a method of reducing blood leptin in a subject. Antcin K exerts prominent antidiabetic and antihyperlipidemic effects through regulation of membrane GLUT4, AMPK, Akt PPAR?, FAS, and PPAR? protein expressions and G6Pase, DGAT2, SREBP-1c, aP2, apoCIII, SREBP2, and PPAR? mRNA expressions.
Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
Abstract: The present invention relates to compounds, intermediates used in the preparation of such compounds, processes for the preparation of such compounds of the formula V and formula VI and such intermediates, pharmaceutical compositions composing such compounds of the formula V and such compounds of the formula VI, and the uses of such compounds of the formula V and such compounds of the formula VI as anti-inflammatory, antiobesity and cardioprotective agents.
Abstract: The present disclosure provides methods of reducing the level of acetylated Tau in a neuron or a glial cell in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate. The present disclosure provides methods of treating a tauopathy in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate.
Type:
Application
Filed:
January 15, 2016
Publication date:
December 28, 2017
Inventors:
Li Gan, Xu Chen, Min Xie, Eric M. Verdin
Abstract: The invention relates to medicine and specifically to methods for treating recurring forms of diseases related to the family of herpes viruses. A method for treating recurring diseases of the skin and mucous membranes caused by HSV-1 and HSV-2 involves applying a preparation to an affected area, said preparation including a base containing 0.5% or 1% of an active substance, namely a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula (I): where X is Na, K, NH4; the preparation is applied twice daily for 3-5 days and, should prodromes appear, a second course of treatment is carried out, in which the preparation is applied 1-2 times daily for 2-3 days; the base containing the active substance can be in the form of a cream, an ointment, a gel, a suspension, suppositories, a patch or a film.
Type:
Application
Filed:
August 14, 2017
Publication date:
December 28, 2017
Inventors:
Viktor Veniaminovich Tets, Georgy Viktorovich Tets
Abstract: Disclosed are formulations comprising brincidofovir. The formulations can be intravenous formulations. The formulations can be used in cases where a subject experiences gastrointestinal issues in response to oral administration of brincidofovir. The formulations can also be used in cases where oral administration of drug is not possible due to underlying conditions or concern around inadequate oral absorption.
Type:
Application
Filed:
June 28, 2017
Publication date:
December 28, 2017
Inventors:
Roy Wendell WARE, Mohammed Anowrul KABIR, Odin Johann Naderer, Irma Marisa GROSSI
Abstract: The present invention relates to the pharmaceutical field, and in particular to a ginsenoside composition, and preparation method and use thereof. The ginsenoside composition comprises rare ginsenosides Rh4, Rk3, Rk1 and Rg5. By conducting a systematic research on the change in active ingredients during the steaming process of ginseng and applying response surface to design experiments so as to optimize the ginseng processing process, a processing method wherein there is the most significant change in ginsenoside ingredients relative to the original medicinal material, and especially a processing method for efficiently obtaining rare ginsenoside ingredients, is unexpectedly discovered in the present invention. Through later screening of pharmacological activities, the inventors further unexpectedly discovered that the processed ginseng product rich in rare ginsenosides has a significant efficacy in invigorating kidney yang.
Abstract: The present invention relates to composition for enhancing immunity, comprising ginsenoside F1 as an active ingredient. Specifically, the composition according to the present invention promotes degranulation activity and cell-killing activity of natural killer cells, and increases expressions of cell-killing factors, thereby being effectively used as an immune enhancer.
Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
September 8, 2017
Publication date:
December 28, 2017
Applicant:
Lumena Pharmaceuticals LLC
Inventors:
Bronislava Gedulin, Michael Grey, Niall O'Donnell
Abstract: Disclosed are methods and preparations useful for reducing fat at a targeted area(s) on a human. The preparations comprise as an active ingredient an adipolysis enhancing (i.e., fat-melting) amount of an active ingredient, paeoniflorin (PF). The preparations may be provided as an injectable preparation or as a topically applied preparation, such as in the form of a crème or lotion. In topical preparations, the active ingredient paeoniflorin may be contained within nanospheres, such as albumin nanospheres. The PF-containing preparations may also include a permeant, such as azone. The method may be accompanied by the application of ultrasound to the area being treated prior to, during or after, or prior to, during, and after application of the paeoniflorin preparation to an area of the body in which fat reduction is desired.
Abstract: The present invention relates to a pharmaceutical composition comprising topiramate, and more particularly, to a solid pharmaceutical composition comprising topiramate, a cellulose derivative, a lipid and optional pharmaceutical excipients, wherein the weight ratio of topiramate to the cellulose derivative is 100:10 to 100. The pharmaceutical compositions of the present invention have excellent formulation properties as well. The pharmaceutical compositions of the present invention can be used for monotherapy for patients who are newly diagnosed with epilepsy, or patients who have been previously treated with combination therapy and now for monotherapy. They can also be used for the add-on treatment of partial seizures in adults and children aged 2 to 16 years.
Abstract: The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.
Type:
Application
Filed:
January 8, 2016
Publication date:
December 28, 2017
Applicants:
AbbVie Inc., Liverpool School of Tropical Medicine
Inventors:
Thomas W. VON GELDERN, Dale J. KEMPF, Kennan C. MARSH, Mark John TAYLOR, Stephen Andrew WARD, Louis FORD, Joseph TURNER
Abstract: The present invention relates to a novel use of an Anemarrhena asphodeloides Bunge extract and the like, and provides a composition for preventing or treating colitis, including an Anemarrhena asphodeloides Bunge extract, a fraction thereof or a compound isolated therefrom as an active ingredient. In addition, the present invention relates to a novel use of a combined extract of medicinal herbs, and provides a composition for preventing or treating colitis, including an Anemarrhena asphodeloides Bunge extract, a Galla Rhois extract, a Codonopsis lancellata extract, and the like as active ingredients, or including an Anemarrhena asphodeloides Bunge extract, a Coptis japonica Makino extract, and the like as active ingredients. According to the present invention, the Anemarrhena asphodeloides Bunge extract and the like or the combined extract can be used as a food or medical materials constituting a pharmaceutical composition or a nutraceutical composition.
Type:
Application
Filed:
August 29, 2017
Publication date:
December 28, 2017
Inventors:
DONG-HYUN KIM, MYUNG JOO HAN, SE EUN JANG
Abstract: This document relates to methods and materials for reducing the risk of infection after a shoulder surgery or medical procedure. For example, this document relates to methods and materials for using a topical composition containing clindamycin or erythromycin to reduce the risk of or to prevent infection associated with shoulder surgeries or medical procedures.
Type:
Application
Filed:
September 8, 2017
Publication date:
December 28, 2017
Applicant:
Mayo Foundation for Medical Education and Research
Abstract: Provided herein is technology relating to predicting a subject's resistance or responsiveness to a decitabine based therapy and particularly, but not exclusively, to methods, compositions, and related uses for predicting a subject's resistance or responsiveness to a decitabine based therapy wherein the subject is diagnosed with chronic myelomonocytic leukemia.
Type:
Application
Filed:
December 21, 2015
Publication date:
December 28, 2017
Applicant:
The Regents of the University of Michigan
Inventors:
Maria Figueroa, Kirsten Meldi, Tingting Qin, Valeria Santini
Abstract: The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.
Abstract: Provided is a chondroitin sulfate derivative having a structure cross-linked with a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.
Abstract: Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.
Type:
Application
Filed:
January 7, 2016
Publication date:
December 28, 2017
Applicant:
Trigemina, Inc.
Inventors:
David C. YEOMANS, Dean CARSON, Ramachandran THIRUCOTE
Abstract: A method of treating water to reduce or prevent bacterial infection in an aquatic organism may include administering a particulate kaolin clay to the water in a dosage sufficient to reduce the presence of at least one undesirable bacterial species present in the water, wherein the particulate kaolin clay has at least one property selected from: (a) a BET surface area of at least about 25 m2/g; (b) a particle size distribution such that at least about 80% by weight of the particles of kaolin clay have an equivalent spherical diameter of less than 2 microns as measured by Sedigraph; and (c) a particle size distribution such that at least about 25% by weight of the particles of kaolin clay have an equivalent spherical diameter of less than 0.25 microns as measured by Sedigraph. The method may further include contacting an aquatic organism with the treated water.
Abstract: The invention relates to a hair restorer preparation or food supplement (100, 100a-100c) for oral administration, comprising L-cysteine and zinc, wherein the hair restorer preparation respectively food supplement (100, 100a-100c) comprises copper, calcium, magnesium, silicium and cholecalciferol, and wherein the composing substances or substance compositions (S-Z) composing the hair restorer preparation respectively food supplement (100, 100a-100c) are determined in their dosage by means of tests and/or measurements and/or questionnaire evaluations (A-H) and are adaptable to the individual organic nutrients supply requirements of a female or a male customer (200, 200a-200d).